Document is current
Any future updates will be listed below
-
Authors
Shen, Li
Claggett, Brian L.
Jhund, Pardeep S.
Abraham, William T.
Desai, Akshay Suvas
Dickstein, Kenneth
Gong, Jianjian
Køber, Lars V.
Lefkowitz, Marty P.
Rouleau, Jean L.
Shi, Victor C.
Swedberg, Karl
Zile, Michael R.
Solomon, Scott D.
McMurray, John J. V.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01035255 at ClinicalTrials.govnct00853658 at ClinicalTrials.govDocuments that mention this clinical trial
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)61227-6
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
https://doi.org/10.1161/circulationaha.122.063642
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
https://doi.org/10.1161/circheartfailure.122.010111
Medical therapy for chronic heart failure
https://doi.org/10.1016/s0140-6736(11)61038-6
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
https://doi.org/10.1007/s00392-021-01888-x
Documents that mention this clinical trial
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
https://doi.org/10.1161/circulationaha.122.063642
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
https://doi.org/10.1007/s00392-021-01888-x
- License Information
-
More Information
Article History
Received: 25 August 2020
Accepted: 1 June 2021
First Online: 8 June 2021
Declarations
:
: Li Shen and Brian Claggett have nothing to disclose. ATMOSPHERE and PARADIGM-HF were funded by Novartis and all authors (except Li Shen and Brian Claggett) or their institutions were paid by Novartis for their participation in one or both of these trials. Jianjian Gong, Marty Lefkowitz and Victor Shi are employees of Novartis.
